Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
DaVita Inc. (NYSE: DVA) has scheduled its quarterly conference call to discuss first-quarter results on May 8, 2023, at 5:00 p.m. Eastern Time. The results will be released after the market closes on the same day. The call will be available via webcast on the DaVita investor relations webpage. Investors can join by dialing 877-918-6630 (or 517-308-9042 internationally) and using the password 'Earnings'. For those unable to attend, a replay will be accessible on DaVita's website without a telephone replay option. As of December 31, 2022, DaVita served 200,000 patients across 2,724 outpatient dialysis centers in the U.S. and operated 350 centers in 11 other countries, focusing on improving care delivery and clinical outcomes for kidney health.
Lex Ferenda Litigation Funding LLC (LF2) announced its expansion into Denver, Colorado, welcoming Andrew Kelley as Managing Director of Underwriting and Risk. Kelley, previously with DaVita Inc. (NYSE: DVA), brings extensive experience in dispute resolution, reportedly recovering hundreds of millions for clients. This strategic move aims to enhance LF2's capabilities in the US litigation finance market, promising quicker decisions and improved client engagement. The firm emphasizes its commitment to high standards in risk management and investment processes, fostering supportive partnerships for clients navigating litigation costs.
Medtronic and DaVita have launched Mozarc Medical, an independent kidney health technology company aimed at enhancing patient care. Announced on April 1, 2023, Mozarc Medical will leverage expertise from Medtronic's former Renal Care Solutions unit and DaVita's leadership to innovate in kidney health technologies. CEO Ven Manda emphasized the need for patient-centered solutions, particularly as demand for in-home kidney care rises. Both companies hold equal equity stakes in Mozarc Medical, which had combined revenues of $64 million, $63 million, and $70 million in the first three quarters of Medtronic's fiscal year 2023.
On March 13, 2023, DaVita Inc. (NYSE: DVA) announced that its Chief Financial Officer, Joel Ackerman, will participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on March 14, 2023, at 3:05 p.m. EDT. Investors can access the live webcast by visiting the Barclays page and registering for free. DaVita, a leader in kidney care services, serves 200,000 patients across 2,724 outpatient dialysis centers in the U.S. and 350 centers in 11 other countries.
DaVita Inc. reported financial results for Q4 and the year ended December 31, 2022, with consolidated revenues of $2.917 billion for Q4 and $11.610 billion for the full year. Operating income for Q4 was $256 million while adjusted operating income reached $317 million. Diluted EPS from continuing operations was $0.59 for Q4 and $5.71 for the year. Notably, total U.S. dialysis treatments showed a daily decrease of 1.3% from the prior quarter. The company faced challenges with rising patient care costs and significant expenses linked to center closures and advocacy efforts against union initiatives.